These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23316217)

  • 1. PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma.
    Kimura O; Kondo Y; Shimosegawa T
    PPAR Res; 2012; 2012():574180. PubMed ID: 23316217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.
    Zhao Y; Tan H; Zhang X; Zhu J
    J Cell Mol Med; 2023 Nov; 28(5):e18042. PubMed ID: 37987033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
    Choudhary NS; Kumar N; Duseja A
    J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of hepatocellular carcinoma (HCC).
    Pan Y; Li Y; Fan H; Cui H; Chen Z; Wang Y; Jiang M; Wang G
    Biomed Pharmacother; 2024 Jul; 177():117089. PubMed ID: 38972148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.
    Yu Q; Wu L; Ji J; Feng J; Dai W; Li J; Wu J; Guo C
    J Hepatocell Carcinoma; 2020; 7():271-288. PubMed ID: 33150145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.
    de Gottardi A; Pazienza V; Pugnale P; Bruttin F; Rubbia-Brandt L; Juge-Aubry CE; Meier CA; Hadengue A; Negro F
    Aliment Pharmacol Ther; 2006 Jan; 23(1):107-14. PubMed ID: 16393287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids.
    Zhou YC; Waxman DJ
    Environ Health Perspect; 1998 Aug; 106 Suppl 4(Suppl 4):983-8. PubMed ID: 9703482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.
    Schoonjans K; Staels B; Auwerx J
    Biochim Biophys Acta; 1996 Jul; 1302(2):93-109. PubMed ID: 8695669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
    Kallwitz ER; McLachlan A; Cotler SJ
    World J Gastroenterol; 2008 Jan; 14(1):22-8. PubMed ID: 18176957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma.
    Hsu HT; Chi CW
    J Hepatocell Carcinoma; 2014; 1():127-35. PubMed ID: 27508182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
    Ibabe A; Herrero A; Cajaraville MP
    Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RLA8-A New and Highly Effective Quadruple PPAR-
    Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
    J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.
    Suresh D; Srinivas AN; Kumar DP
    Front Oncol; 2020; 10():601710. PubMed ID: 33330100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-δ of orange-spotted grouper exerts antiviral activity against fish virus and regulates interferon signaling and inflammatory factors.
    Wang Y; Yu Y; Wang Q; Wei S; Wang S; Qin Q; Yang M
    Fish Shellfish Immunol; 2019 Nov; 94():38-49. PubMed ID: 31470135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
    Guan Y
    Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease.
    Li YY; Cao CY; Zhou YL; Nie YQ; Cao J; Zhou YJ
    Arab J Gastroenterol; 2020 Sep; 21(3):162-168. PubMed ID: 32451200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.